Please Note:

The Open Access Repository will be moving to a new authentication system on the 1st of November.

From this date onwards, account holders will be required to login using their University of Tasmania credentials.
If your current repository username differs from your University username, please email so we can update these details on your behalf.

Due to the change, there will be a short outage of the repository from 9am on the morning of the 1st of November

Open Access Repository

Acorda Therapeutics: Rebuilding the Spinal Cord

Murray, F and Kolesnik, M and Enriquez, J and West, J (2004) Acorda Therapeutics: Rebuilding the Spinal Cord. Other. Harvard Business School.

Full text not available from this repository.


Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic in-licensing choices, including what disease indication, what stage of development, how many molecules, and on what terms.

Learning Objective:
To allow students to examine a portfolio of choices and their impact on the overall business rather than on a single licensing decision.

New York, NY; United States; Biotechnology industry; start-up; 2003

Item Type: Report (Other)
Publisher: Harvard Business School
Identification Number - DOI: Case (Field) 9-604-014
Date Deposited: 02 Jan 2008 06:03
Last Modified: 16 Jul 2008 16:41
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page